This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Growth Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 21st
Why Is Bruker (BRKR) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here is Why Growth Investors Should Buy Bruker (BRKR) Now
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Top Ranked Growth Stocks to Buy for March 4th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 4th
Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts
by Zacks Equity Research
Bruker's (BRKR) CALID and NANO groups hold promise.
Bruker (BRKR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
Bruker (BRKR) Meets Q4 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0.00% and 1.67%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Bruker (BRKR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured expert Kevin Matras highlights: Crocs, Novanta, Abercrombie & Fitch and Bruker
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Crocs, Novanta, Abercrombie & Fitch and Bruker
Tap 4 Best-Performing Liquid Bets to Boost Portfolio Returns
by Zacks Equity Research
Here are four top-notch liquid stocks that can make a winning portfolio for investors.
New Strong Buy Stocks for December 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Top Ranked Growth Stocks to Buy for December 26th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 26th:
Top Ranked Growth Stocks to Buy for December 24th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 24th
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Bruker Profits from NANO & CALID, New Buyout Holds Promise
by Zacks Equity Research
Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.
Bruker (BRKR) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Outlook for Scientific Instruments Industry Looks Promising
by Zacks Equity Research
The Zacks Instruments - Scientific industry is benefiting from strong growth prospects in emerging markets, robust end-market demand and increasing spending on health care.
Bruker (BRKR) Q3 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
We are upbeat about Bruker's (BRKR) current focus on product development through higher R&D.
Bruker (BRKR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 23.33% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker to Expand Molecular Diagnostics Arm With Hain Buyout
by Zacks Equity Research
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.
Bruker Unveils New Mass-Spectrometry Products, Boosts CALID
by Zacks Equity Research
Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.
Bruker (BRKR) Up 2.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.